Add like
Add dislike
Add to saved papers

Primary versus secondary esophageal motility disorders: diagnosis and implications for treatment.

Ambulatory pH monitoring is essential in patients with a manometric pattern of either diffuse esophageal spasm (DES) or nutcracker esophagus (NE), since these diseases can be considered a primary esophageal motility disorder (PEMD) only in the absence of gastroesophageal reflux disease (GERD). If GERD is present, the motility abnormality is considered secondary, and treatment is directed toward reflux. The aims of this study were to determine in patients with a manometric picture of DES and NE (1) if symptoms alone can distinguish PEMD from GERD and (2) the value of ambulatory pH monitoring. A total of 180 patients fulfilled the manometric criteria for NE, and 124 (69%) of them had GERD detected by ambulatory pH monitoring. Among the 56 patients with PEMD, 31 (55%) were taking proton pump inhibitors on the assumption that GERD was present. Chest pain prevalence was similar when the two groups were compared; however, the symptom was more severe in the PEMD patients. Heartburn prevalence and severity was higher in the GERD group. A total of 121 patients fulfilled the manometric criteria for DES, and 73 (60%) of them had GERD detected by ambulatory pH monitoring. Among the 48 patients with PEMD, 39 (81%) were taking proton pump inhibitors. Dysphagia was more prevalent in the PEMD group. These data show that (1) 2 of 3 of patients with a manometric picture of NE or DES have GERD and (2) symptoms did not distinguish PEMD from GERD. Esophageal manometry and pH monitoring are essential to distinguish PEMD from GERD and to guide appropriate therapy.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app